Given that CDKN2A encodes tumor suppressors and the current literature correlates only homozygous CDKN2A loss with prognosis and grade in gliomas and meningiomas, determining hemizygous loss in our cohort was deemed irrelevant. The gene discussed is CDKN2A; the disease is central nervous system cancer.